|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase Ⅱ California Cancer Consortium Trial显示文摘 | Lara PN Jr Gandara DR Longmate J | 2001 | Cancer Chemother Pharmacol2001，48，1： | 1 |
| 2 | High-dose toremifene as a cisplatin modulator in metastatic non-small-cell lung cancer:targed plasma levels are achievable clinically显示文摘 | Lara PN Jr Gandara DR Wurz GT | 1998 | Cancer Chemother Pharmacol1998，42，6： | 1 |
| 3 | Phase Ⅱ trial of irinote-ean/cisplatin compared with etoposide/cisplatin in extersive-stage small-cen lung cancer:clinical and pharmarogenomic results from SWOG SO124 显示文摘 | Lara P N Jr Natale R Crouley J | 2009 | J Clin Onco12009，27，15： | 1 |
| 4 | Phase Ⅲ trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer:clinical and pharmacogenomic results from SWOGS0124显示文摘 | Lara PN Jr Natale R Crowley J | 2009 | J Clin Oncol2009，27，15： | 1 |
| 5 | Prognostic signif- icane of the distribution of neck node metastasis from oral carcinoma 显示文摘 | Kowalski LP Bagitetto R Lara JR | 2000 | Head Neck2000，22，3： | 1 |
| 6 | XL647-a multitargeted tyrosine kinase inhibitor: results of a phase H study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib显示文摘 | Pietanza MC Lynch TJ Jr Lara PN Jr etal | 2012 | J Thorac Oncol2012，7，1： | 1 |
| 7 | Photoluminescence emissions of Ca_(1-x)WO_(4):xEu^(3+):Bridging between experiment and DFT calculations显示文摘In this work,the impact of the doping process on the photoluminescence emission of CaWO_(4) as a function of the concentration of Eu^(3+) cation(0.01 mol%,0.02 mol%,0.04 mol%,0.06 mol%,0.08 mol%,and 0.10 mol%) is discussed in detail.Ca_(1-x)WO~4:xEu^(3+) samples were successfully synthesized by a simple coprecipitation method followed by microwave irradiation.The blue shift in the absorption edge confirms the quantum confinement effect and the band gap energy covers the range from 3.91 to 4.18 eV,as the amount of Eu^(3+) cations increases.The experimental results are sustained by first-principles calculations,at the density functional theory level,to decipher the geometry and electronic properties,thereby enabling a more accurate and direct comparison between theory and experiment for the Ca_(1-x)WO_(4):xEu^(3+) structure. | Amanda Fernandes Gouveia Marcelo Assis Lara Kelly Ribeiro Aline Estefany Brandao Lima Eduardo de Oliveira Gomes Daniele Souza Yara Gobato Galvao Ieda Lucia Viana Rosa Geraldo Eduardo da Luz Jr Eva Guillamón Elson Longo Juan Andrés Miguel Angel San-Miguel | 2022 | Journal of Rare Earths2022，40，10： | 1 |
| 8 | Prognostic significance of the distribution of neck node metastasis from oral carcinoma显示文摘 | Kowalski LP Bagietto R Lara JR | 2000 | Head Neck2000，22，3： | 1 |
| 9 | Activity of highdose toremifene plus eispLatin in platinum-treated nonsmall-cell lung cancer:,a phase Ⅱ California Cancer Consortium Trial显示文摘 | Lara P Jr Gandara DR Longmate J | 2001 | Cancer Chemother Pharmacol2001，48，1： | 1 |
| 10 | Prognostic significance of the distribution of neck node metastasis from oral carcinoma 显示文摘 | Kowalski LP Bagietto R Lara JR | 2000 | Head Neck2000，22，： | 1 |
| 11 | Concurrent chemoradiation strategies in the management of unresectable stage Ⅲ non-small-cell lung cancer显示文摘 | Lara PN Jr Goldberg Z Davies A | 2002 | Clin Lung Cancer2002，3，2： | 1 |
| 12 | Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive - stage small - cell lung cancer: clinical and pharmacogenomic results from SWOG S0124 显示文摘 | Lara P N Jr Natale R Crowley J | 2009 | J Clin Oncol2009，27，15： | 1 |
| 13 | Phase m trial of Irinotecan/Cisplatin compared with Etoposide/Cisplatin in extensive-stage small-cell lung cancer: Clinical and pharmacoge- nomic results from SWOG S0124 显示文摘 | Lara PN Jr Natale R Crowley J | 2009 | J Clin Oncol2009，27，15： | 1 |
| 14 | Docetaxel in nonsmall cell lung cancer显示文摘 | Davies AM Lara PN Jr Mack PC | 2003 | Expert Opin Pharmacother2003，4，4： | 1 |
| 15 | The cavum septi pellucidi: a fifth ventricle?显示文摘 | Alonso JR Covenas R Lara J | 1989 | Acta Anat(Basel)1989，134，4： | 1 |
| 16 | Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer显示文摘 | Rothschild SI Gautschi O Lara PN Jr | 2011 | Curr Opin Oncol2011，23，2： | 1 |
| 17 | Phase Ⅲ trial of irinotecan/cis- platin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer:clinical and pharmacogenomic results from SWOG S0124显示文摘 | Lara PN Jr Natale R Crowley J | 2009 | J Clin Oncol2009，27，15： | 1 |
| 18 | Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group 显示文摘 | Ryan CW Goldman BH Lara PN Jr | 2007 | J Clin Onco12007，25，22： | 1 |
| 19 | Prognostic significance of the distribution of neck node metastasis from oral carcinoma显示文摘 | Kowalski LP Bagietto R Lara JR | 2000 | Head Neck2000，22，3： | 1 |
| 20 | Activity of high-dose toremifene plus cisplatin in platinumol/L-treated non-small-cell lung cancer:a phase Ⅱ california cancer consortiumol/L trial显示文摘 | Lara Jr P N Gandara D R Longmate J | 2001 | Cancer Chemother Pharacol2001，48，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员